ArticleFrontiers in pharmacology2022

Nintedanib Alleviates Experimental Colitis by Inhibiting CEBPB/PCK1 and CEBPB/EFNA1 Pathways.

Hailong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.